Brett G Hollier
Overview
Explore the profile of Brett G Hollier including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
33
Citations
1594
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Westaby D, Jimenez-Vacas J, Figueiredo I, Rekowski J, Pettinger C, Gurel B, et al.
J Clin Invest
. 2024 Sep;
134(18).
PMID: 39286979
The widespread use of potent androgen receptor signaling inhibitors (ARSIs) has led to an increasing emergence of AR-independent castration-resistant prostate cancer (CRPC), typically driven by loss of AR expression, lineage...
2.
Neumann D, Pillman K, Dredge B, Bert A, Phillips C, Lumb R, et al.
RNA Biol
. 2023 Dec;
21(1):1-11.
PMID: 38112323
Epithelial-mesenchymal transition (EMT) plays important roles in tumour progression and is orchestrated by dynamic changes in gene expression. While it is well established that post-transcriptional regulation plays a significant role...
3.
Neumann D, Phillips C, Lumb R, Palethorpe H, Ramani Y, Hollier B, et al.
Mol Biol Cell
. 2023 Nov;
35(2):ar17.
PMID: 38019605
The RNA-binding protein Quaking (QKI) has widespread effects on mRNA regulation including alternative splicing, stability, translation, and localization of target mRNAs. Recently, QKI was found to be induced during epithelial-mesenchymal...
4.
Chawla S, Rockstroh A, Lehman M, Ratther E, Jain A, Anand A, et al.
Nat Commun
. 2022 Sep;
13(1):5680.
PMID: 36167836
Inter and intra-tumoral heterogeneity are major stumbling blocks in the treatment of cancer and are responsible for imparting differential drug responses in cancer patients. Recently, the availability of high-throughput screening...
5.
Tang Y, Rockstroh A, Sokolowski K, Lynam L, Lehman M, Thompson E, et al.
Breast Cancer Res
. 2022 Jan;
24(1):8.
PMID: 35078508
Background: Triple-negative breast cancers (TNBC) have a relatively poor prognosis and responses to targeted therapies. Between 25 and 39% of TNBCs are claudin-low, a poorly differentiated subtype enriched for mesenchymal,...
6.
Xiao M, Hasmim M, Lequeux A, Van Moer K, Tan T, Gilles C, et al.
Cancers (Basel)
. 2021 Apr;
13(5).
PMID: 33803139
CMTM6 is a critical regulator of cell surface expression of PD-L1 in tumor cells, but little is known about the transcriptional regulation of CMTM6. Here we report that the expression...
7.
Nouri M, Massah S, Caradec J, Lubik A, Li N, Truong S, et al.
Clin Cancer Res
. 2020 Jan;
26(7):1678-1689.
PMID: 31919137
Purpose: Patients with metastatic prostate cancer are increasingly presenting with treatment-resistant, androgen receptor-negative/low (AR) tumors, with or without neuroendocrine characteristics, in processes attributed to tumor cell plasticity. This plasticity has...
8.
Sarkar P, Lee W, Williams E, Lubik A, Stylianou N, Shokoohmand A, et al.
Front Endocrinol (Lausanne)
. 2019 Aug;
10:481.
PMID: 31379747
Androgen deprivation therapy (ADT) is the standard treatment for advanced prostate cancer (PCa), yet many patients relapse with lethal metastatic disease. With this loss of androgens, increased cell plasticity has...
9.
Stylianou N, Lehman M, Wang C, Fard A, Rockstroh A, Fazli L, et al.
Oncogene
. 2018 Dec;
38(13):2436.
PMID: 30510231
Following the publication of the above article, the authors noted an error in Figure 4, panel B. The colours of the localized and mCRPC samples were accidentally switched. The authors...
10.
Stylianou N, Lehman M, Wang C, Fard A, Rockstroh A, Fazli L, et al.
Oncogene
. 2018 Sep;
38(7):913-934.
PMID: 30194451
The propensity of cancer cells to transition between epithelial and mesenchymal phenotypic states via the epithelial-mesenchymal transition (EMT) program can regulate metastatic processes, cancer progression, and treatment resistance. Transcriptional investigations...